Shikimic Acid Multidentate Splitters for Nucleic Acid Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a need for alternative chemical functionalities to couple cargo moieties and ligands for delivering therapeutic nucleic acids to cells, particularly for targeted delivery to liver cells.

Innovation Solution

The use of multidentate 'splitter' compounds derived from or chemically related to shikimic acid to join monosaccharide ligands and nucleic acids, providing a novel approach for coupling targeting and cargo moieties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional coupling chemistries are used to link ligands and cargo moieties to branched core structures, then existing complexes can be prepared, but alternative chemical functionalities are needed to improve targeting and pharmacokinetic properties

Engineering Contradiction:
Improvetargeting efficiencyVSAvoidchemical functionality options
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by modifying the chemical functionality of the coupling agents. Specifically, it introduces multidentate splitters derived from shikimic acid, which contain multiple carboxylate groups that can form coordinate covalent bonds with metal ions. This chemical parameter change enables improved targeting efficiency and pharmacokinetic properties compared to conventional coupling chemistries.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite materials by creating complexes that integrate multiple components: multidentate shikimic acid-derived splitters, metal ions (such as gallium or indium), monosaccharide ligands (like GalNAc), and cargo moieties (such as oligonucleotides). This composite structure combines the advantages of each component to achieve superior targeting and delivery performance.

Inventive Principle:
Principle #40Composite materials

2Productivity

If multivalent complexes with multiple ligands and cargo moieties are constructed using branched core structures, then targeted delivery capability is enhanced, but chemical complexity of coupling increases

Engineering Contradiction:
Improvedelivery efficiencyVSAvoidchemical structure complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the complex into distinct functional modules: a multidentate splitter core derived from shikimic acid, metal ion coordination centers, ligand attachment points, and cargo moieties. This modular segmentation allows for systematic construction of multivalent complexes while managing chemical complexity through standardized coupling interfaces.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The multidentate shikimic acid-derived splitters serve multiple functions simultaneously: they act as structural cores, provide metal ion coordination sites, offer multiple attachment points for ligands and cargo moieties, and enable controlled assembly of complex structures. This multi-functionality reduces the need for separate components and simplifies the overall chemical architecture.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The described compounds exhibit improved targeting, increased activity, and enhanced pharmacokinetic properties, enabling effective delivery of nucleic acids to liver cells.

Implementation Method 1

These compounds comprise specific monosaccharides which are capable of binding to asialoglycoprotein receptors (ASGPRs)

Methodology Applied
Scientific EffectSaccharide-binding: Adsorption

Data Source

PatentUS20250064944A1Multivalent cargo-carrying complexes and uses thereof
Publication Date: 2025.02.27 ASTRAZENECA AB
  • US20250064944A1 patent drawing
  • US20250064944A1 patent drawing
  • US20250064944A1 patent drawing

AI summary

Provided are multivalent saccharide-containing compounds which are bonded to nucleic acids. These compounds contain a shikimic acid-derived core and are useful for delivering nucleic acids to cells or tissues, e.g. for use in therapeutic treatments. Also provided are pharmaceutical compositions comprising the aforementioned compounds and medical uses of the same, including their use in treating or preventing conditions such as liver diseases.